Kura Oncology KURA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $71.64M+6.2% | $67.48M+6.1% | $63.62M+12.9% | $56.34M+3.3% | $54.52M+1.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $260.36M+3.7% | $251.07M+5.1% | $238.93M+12.3% | $212.73M+12.2% | $189.67M+11.6% | ||
| —— | —— | —— | —— | $80.67M+4.6% | ||
| —— | —— | —— | —— | —— | ||
| -$317.75M-4.6% | -$303.63M-26.6% | -$239.82M-9.2% | -$219.71M-8.0% | -$203.44M-5.3% | ||
| -443.5%+6.4pp | -449.9%-73.0pp | -377%+13.0pp | -390%-16.8pp | -373.2%-14.6pp | ||
| $1.47M-3.0% | $1.51M-3.6% | $1.57M-1.2% | $1.59M-0.9% | $1.6M-1.0% | ||
| $24.72M-7.7% | $26.77M+0.1% | $26.75M+1.4% | $26.37M+3.8% | $25.4M+11.2% | ||
| $23.26M-7.9% | $25.26M+0.3% | $25.18M+1.6% | $24.78M+4.1% | $23.8M+12.1% | ||
| -$294.49M-5.8% | -$278.37M-29.7% | -$214.64M-10.1% | -$194.93M-8.5% | -$179.64M-4.5% | ||
| —— | —— | —— | —— | $1.74M-13.8% | ||
| -$294.57M-5.7% | -$278.67M-28.5% | -$216.88M-10.0% | -$197.17M-8.4% | -$181.89M-4.5% | ||
| -411.2%+1.8pp | -412.9%-72.0pp | -340.9%+9.1pp | -350%-16.4pp | -333.6%-10.7pp | ||
| -$3.35-5.3% | -$3.18-28.2% | -$2.48-9.7% | -$2.26-7.6% | -$2.10-3.4% | ||
| -$3.35-5.3% | -$3.18-28.2% | -$2.48-9.7% | -$2.26-7.6% | -$2.10-3.4% | ||
| 351.5M+0.3% | 350.3M+0.4% | 348.8M+0.2% | 348.1M+0.3% | 347.2M+1.0% | ||
| 351.5M+0.3% | 350.3M+0.4% | 348.8M+0.2% | 348.1M+0.3% | 347.2M+1.0% | ||
| —— | $57K+33.3% | $42.75K+50.0% | $28.5K+100% | $14.25K— | ||
| -$295.92M-6.3% | -$278.41M-28.2% | -$217.08M-10.8% | -$196M-8.8% | -$180.1M-4.7% | ||
| $24.72M-7.7% | $26.77M+0.1% | $26.75M+1.4% | $26.37M+3.8% | $25.4M+11.2% | ||
| —— | —— | —— | —— | —— | ||
| $71.64M+6.2% | $67.48M+6.1% | $63.62M+12.9% | $56.34M+3.3% | $54.52M+1.2% | ||
| -$317.75M-4.6% | -$303.63M-26.6% | -$239.82M-9.2% | -$219.71M-8.0% | -$203.44M-5.3% | ||
| -$316.6M-4.6% | -$302.6M-26.6% | -$238.99M-9.2% | -$218.83M-8.0% | -$202.59M-5.3% | ||
| -$316.6M-4.6% | -$302.6M-26.6% | -$238.99M-9.2% | -$218.83M-8.0% | -$202.59M-5.3% | ||
| -441.9%+6.5pp | -448.4%-72.8pp | -375.7%+12.8pp | -388.4%-16.8pp | -371.6%-14.6pp | ||
| -$317.75M-4.6% | -$303.63M-26.6% | -$239.82M-9.2% | -$219.71M-8.0% | -$203.44M-5.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Kura Oncology's revenue?
- Kura Oncology (KURA) generated $71.6M in revenue over the trailing twelve months, up 31.4% year over year.
- Is Kura Oncology profitable?
- Kura Oncology is not currently profitable: it reported a net loss of $294.6M over the trailing twelve months, a -411.2% net margin.
- What is Kura Oncology's earnings per share?
- Kura Oncology's diluted EPS over the trailing twelve months is $-3.35.
- Where does Kura Oncology's income statement data come from?
- Every line is extracted from Kura Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
